Manufacturer offers money-back guarantee on BPH drug

October 14, 2004

Sanofi-Synthelabo Inc. has introduced a money-back guarantee program for BPH patients not satisfied after taking extended-release alfuzosin hydrochloride (Uroxatral) as directed by their physician.

Sanofi-Synthelabo Inc. has introduced a money-back guarantee program for BPH patients not satisfied after taking extended-release alfuzosin hydrochloride (Uroxatral) as directed by their physician.

The guarantee program provides up to a 30-day reimbursement of the patient's out-of-pocket prescription cost if the patient's urologist determines that alfuzosin was not right for him. The company will also reimburse costs if the patient experiences side effects including, but not limited to, ejaculatory or erectile dysfunction.

Alfuzosin is a uroselective alpha-blocker.